India to Mozambique: Artemether Export Trade Route

To import Artemether formulations into Mozambique, the following approvals and registrations are necessary:

• Marketing Authorization: All pharmaceutical products must obtain marketing authorization from ANARME prior to importation, distribution, or sale in Mozambique.

• Dossier Submission: Applicants are required to submit a comprehensive dossier that includes pharmaceutical information, clinical and non-clinical data to ascertain the quality, safety, and efficacy of the pharmaceutical product.

• Good Manufacturing Practice (GMP) Certification: A valid GMP certificate for each manufacturing site, demonstrating compliance with WHO GMP standards or other equivalent systems, is mandatory. The GMP certificate must be specific to the site and issued within the last two years by ANARME or entities officially recognized by ANARME. (cmam.gov.mz)

• Certificate of Pharmaceutical Product (CoPP): A CoPP, issued in the WHO format by the relevant authority in the exporting country, confirming authorization for export to Mozambique, is required. (cmam.gov.mz)

• Product Labeling: Product labels must state “manufactured in” followed by the actual manufacturing site. Contract manufacturing arrangements (“manufactured for”) are not permitted. (cmam.gov.mz)

Specific timelines for approval and product registration fees are not publicly disclosed and may vary based on the complexity of the application and ANARME's review process.

Indian exporters of Artemether formulations must adhere to the following quality and GMP standards to supply Mozambique:

• GMP Compliance: Manufacturing facilities must comply with WHO GMP standards or equivalent systems. A valid GMP certificate, issued within the last two years by ANARME or entities officially recognized by ANARME, is required. (cmam.gov.mz)

• Dedicated Facilities: Pharmaceutical formulations containing beta-lactams, cephalosporins, cytotoxic substances, hormones, rifampicin, or iron compounds must be manufactured in dedicated facilities to prevent cross-contamination. (cmam.gov.mz)

As of March 2026, specific information regarding Indian facilities currently approved by ANARME, recent inspections, or regulatory actions against Indian pharmaceutical companies by ANARME is not publicly available.

In July 2024, India and Mozambique signed a Memorandum of Understanding (MoU) for the recognition and acceptance of the Indian Pharmacopoeia in Maputo. This agreement is expected to facilitate mutual benefits for pharmaceutical trade and the health sector between the two countries.

No additional regulatory changes, new guidelines, mutual recognition agreements, or policy shifts affecting Indian pharmaceutical exports to Mozambique have been publicly reported in the past 18 months.

Malaria remains a significant public health challenge in Mozambique, with high prevalence rates necessitating substantial demand for effective antimalarial treatments. Artemether-based formulations, particularly in combination therapies like Artemether-Lumefantrine, are central to the country's malaria treatment protocols. In 2024, the market for Artemether formulations in Mozambique was valued at approximately $11.8 million, with imports from India accounting for the entirety of this market segment. The primary drivers of this demand include the high incidence of malaria, ongoing public health initiatives aimed at malaria control, and international support for antimalarial programs. Domestic production of Artemether formulations is minimal, making Mozambique heavily reliant on imports to meet its antimalarial medication needs.

Mozambique imposes a 0% import duty on finished pharmaceutical formulations under HS code 30046000, which includes Artemether-based products. This exemption is part of the country's strategy to ensure the affordability and availability of essential medicines. Additionally, Mozambique is a member of the Southern African Development Community (SADC), which promotes regional trade integration and may influence tariff structures favorably for pharmaceutical imports. There are no specific anti-dumping duties reported on pharmaceutical imports from India, indicating a stable trade relationship in this sector.

India is the predominant supplier of Artemether formulations to Mozambique, accounting for 100% of the $11.8 million import market in 2024. This dominance is attributed to India's robust pharmaceutical manufacturing capabilities and cost-effective production, which align with Mozambique's need for affordable antimalarial treatments. While other countries produce Artemether formulations, their presence in the Mozambican market is negligible, primarily due to higher pricing and less established trade relationships. India's competitive pricing and established supply chains have solidified its position as the leading supplier of Artemether formulations to Mozambique.

India is a leading global producer of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2025. This extensive manufacturing capability extends to antimalarial medications, including formulations containing artemether. The country's pharmaceutical sector comprises over 3,000 companies and more than 10,500 manufacturing facilities, with a significant number dedicated to producing finished dosage forms such as tablets, capsules, syrups, and injections. Notably, India hosts over 262 USFDA-approved manufacturing plants and nearly 1,400 WHO-GMP certified facilities, ensuring adherence to stringent international quality standards. This robust infrastructure enables cost-effective production of high-quality artemether formulations, making India a preferred sourcing destination for global buyers.

When comparing artemether formulation exports, India offers a competitive advantage over China and the European Union (EU) in terms of cost and quality. Indian manufacturers benefit from economies of scale and a well-established supply chain, resulting in lower production costs for finished dosage forms. While China has historically been a major supplier of artemisinin-derived active pharmaceutical ingredients (APIs), its market share in finished pharmaceutical products (FPPs) remains limited, with only a few companies achieving WHO prequalification. The EU, known for its branded generics, often presents higher price points due to stringent regulatory requirements and higher production costs. In contrast, Indian artemether formulations are widely accepted in Mozambique, meeting local regulatory standards and offering a reliable supply track record. This combination of affordability, quality, and regulatory compliance positions India favorably against other sourcing options.

The India-Mozambique supply chain for artemether formulations has demonstrated reliability, supported by India's substantial manufacturing capacity and adherence to Good Manufacturing Practices (GMP). Indian facilities are equipped with advanced packaging and cold chain capabilities, essential for maintaining the stability of artemether formulations, which are sensitive to high temperatures and humidity. While specific data on recent supply disruptions are limited, the consistent export figures and the presence of multiple WHO-GMP certified manufacturers suggest a stable supply chain. Leading Indian pharmaceutical companies continue to invest in capacity expansion and process optimization to meet growing global demand for antimalarial medications. This proactive approach ensures the ability to fulfill large orders and adapt to market needs effectively.

For Mozambican buyers seeking to source artemether formulations from India, the following strategic recommendations are advised:

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of artemether formulations.

• Establish Minimum Order Quantities (MOQs): Negotiate MOQs that align with both procurement budgets and the production capacities of Indian suppliers, balancing cost-effectiveness with supply security.

• Agree on Favorable Payment Terms: Standard payment terms in India-Mozambique pharmaceutical trade often include letters of credit or advance payments. Establish clear terms to maintain smooth transactions and build trust with suppliers.

• Conduct Comprehensive Supplier Qualification: Perform thorough due diligence, including audits of manufacturing facilities, verification of GMP certifications, and assessment of regulatory compliance records, to ensure product quality and supplier reliability.

• Monitor Regulatory Compliance: Stay informed about both Indian and Mozambican regulatory requirements to ensure that sourced artemether formulations meet all necessary standards and facilitate seamless importation.

By adhering to these recommendations, Mozambican buyers can establish a robust and reliable supply chain for artemether formulations, contributing effectively to malaria treatment efforts within the country.

By adhering to this comprehensive supplier qualification framework, Mozambique companies can ensure the procurement of high-quality Artemether formulations from Indian manufacturers, safeguarding public health and maintaining regulatory compliance.